Tissue-Type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance

By Corte M.  

Breast Cancer Research and Treatment, Vol. 90, Iss. 1, 2005-03 ,pp. : 33-40

Springer Publishing Company

Access to resources Recommend Favorite

High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer

By Zhang Hongtuan   Qi Can   Wang Andi   Li Liang   Xu Yong  

Tumor Biology, Vol. 35, Iss. 3, 2014-03 ,pp. : 2025-2028

Springer Publishing Company

Access to resources Recommend Favorite

Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients

By Strojan P.   Budihna M.   S   mid L.   Vrhovec I.   S   krk J.  

European Journal of Cancer, Vol. 34, Iss. 8, 1998-07 ,pp. : 1193-1197

Elsevier

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Elevated Plasma Levels of Urokinase Plasminogen Activator Receptor in Non-small Cell Lung Cancer Patients

By Pappot H.   Hoyer-Hansen G.   Ronne E.   Hansen H.H.   Brunner N.   Dano K.   Grondahl-Hansen J.  

European Journal of Cancer, Vol. 33, Iss. 6, 1997-05 ,pp. : 867-872

Elsevier

Access to resources Recommend Favorite